News
HARP
23.01
0.00%
0.00
Oppenheimer Maintains Outperform on Harpoon Therapeuticsto Outperform
Benzinga · 03/26 14:03
Harpoon Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 03/11 22:48
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/11 21:25
*News On Harpoon Therapeutics Inc. (HARP) Now Under MRK
Dow Jones · 03/11 21:08
Harpoon Therapeutics: Current report
Press release · 03/11 14:26
Harpoon Therapeutics: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 03/11 14:26
Harpoon Therapeutics Inc: Strategic Merger and Corporate Restructuring
TipRanks · 03/11 13:02
Weekly Report: what happened at HARP last week (0304-0308)?
Weekly Report · 03/11 09:22
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck
Healthcare M&A Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck. Harpoon (HARP) has a special meeting set for Friday where shareholders will vote on sale. The deal is tentatively scheduled to close on March 11.
Seeking Alpha · 03/05 15:53
Weekly Report: what happened at HARP last week (0226-0301)?
Weekly Report · 03/04 09:23
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
4 analysts have expressed a variety of opinions on Harpoon Therapeutics over the past quarter. The company is a clinical-stage immunotherapy company developing a novel class of T cell engagers to treat cancer and other diseases. Analysts have set 12-month price targets of $20.25 for the company. The average price target is an 86.98% increase from the previous average of $10.83.
Benzinga · 02/26 17:00
Harpoon Therapeutics Price Target Raised to $23.00/Share From $13.00 by Citigroup
Dow Jones · 02/26 16:58
Harpoon Therapeutics Cut to Neutral From Buy by Citigroup
Dow Jones · 02/26 16:58
Weekly Report: what happened at HARP last week (0219-0223)?
Weekly Report · 02/26 09:24
Harpoon Therapeutics ticks higher after HSR waiting period for Merck deal expires
Harpoon Therapeutics ticks higher after HSR waiting period for Merck deal expires. Merck (MRK) agreed to acquire immunotherapy developer Harpoon Therapeutic for $23.00 per share in cash. Harpoon stock edged higher by 1.4% after the HSR for its planned sale to Merck.
Seeking Alpha · 02/22 14:31
Harpoon Therapeutics Nears Merger Completion with Merck
Harpoon Therapeutics is on course to become a wholly-owned subsidiary of Merck. Merck and Harpoon reached a merger agreement earlier this year. The deal hinges on approval by Harpoon’s stockholders at an upcoming special meeting. HARP stock is down 7% in the last week.
TipRanks · 02/22 13:44
Weekly Report: what happened at HARP last week (0212-0216)?
Weekly Report · 02/19 09:25
Harpoon Therapeutics: Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 03:36
Weekly Report: what happened at HARP last week (0205-0209)?
Weekly Report · 02/12 09:23
More
Webull provides a variety of real-time HARP stock news. You can receive the latest news about Harpoon Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About HARP
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.